Antibody-Drug Conjugates (ADCs) – known as ‘the guided missiles of cancer therapy’ – are forecast to drive robust double-digit growth in contract development and manufacturing over the coming years, positioning them as a pivotal force in the biopharmaceutical landscape. ADCs
Oncology is one of the most important growth markets for the pharmaceuticals industry, partly because of the increasing prevalence of cancer in a world population that is growing and living longer. Ahead of the CDMO Live 2024, Giorgio Bertolini, senior
Olon Ricerca Bioscience is a US-based Contract Research Organisation (CRO) offering speciality chemical manufacturing capabilities.
We spoke to Alessandro Agosti, Senior Director of Scientific Operations about how they partner with customers.
The CDMO Sessions are a series of interviews with leaders at Contract Development and Manufacturing Organisations about what makes their business unique and to share advice for how to create better strategic partnerships. We spoke to the two Vice Presidents
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
